JP2015521615A - 抗体コンジュゲートの調製のための新規方法及び新規抗体コンジュゲート - Google Patents

抗体コンジュゲートの調製のための新規方法及び新規抗体コンジュゲート Download PDF

Info

Publication number
JP2015521615A
JP2015521615A JP2015517843A JP2015517843A JP2015521615A JP 2015521615 A JP2015521615 A JP 2015521615A JP 2015517843 A JP2015517843 A JP 2015517843A JP 2015517843 A JP2015517843 A JP 2015517843A JP 2015521615 A JP2015521615 A JP 2015521615A
Authority
JP
Japan
Prior art keywords
antibody
conjugate
cysteine
group
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015517843A
Other languages
English (en)
Japanese (ja)
Inventor
ジョン・バート
アントニー・ゴドウィン
ジョージ・バデスク
Original Assignee
ポリセリックス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1210838.7A external-priority patent/GB201210838D0/en
Priority claimed from GB201306706A external-priority patent/GB201306706D0/en
Application filed by ポリセリックス・リミテッド filed Critical ポリセリックス・リミテッド
Publication of JP2015521615A publication Critical patent/JP2015521615A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015517843A 2012-06-19 2013-06-19 抗体コンジュゲートの調製のための新規方法及び新規抗体コンジュゲート Pending JP2015521615A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1210838.7A GB201210838D0 (en) 2012-06-19 2012-06-19 Novel process for preparation of antibody conjugates and novel antibody conjugates
GB1210838.7 2012-06-19
GB1306706.1 2013-04-12
GB201306706A GB201306706D0 (en) 2013-04-12 2013-04-12 Novel process for preparation of antibody conjugates and novel antibody conjugates
PCT/GB2013/051593 WO2013190292A2 (en) 2012-06-19 2013-06-19 Novel process for preparation of antibody conjugates and novel antibody conjugates

Publications (1)

Publication Number Publication Date
JP2015521615A true JP2015521615A (ja) 2015-07-30

Family

ID=48699187

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015517843A Pending JP2015521615A (ja) 2012-06-19 2013-06-19 抗体コンジュゲートの調製のための新規方法及び新規抗体コンジュゲート

Country Status (16)

Country Link
US (1) US20150125473A1 (enExample)
EP (1) EP2861261A2 (enExample)
JP (1) JP2015521615A (enExample)
KR (1) KR20150023027A (enExample)
CN (1) CN104379178A (enExample)
AU (1) AU2013279099A1 (enExample)
BR (1) BR112014031613A2 (enExample)
CA (1) CA2876365A1 (enExample)
HK (1) HK1204924A1 (enExample)
IL (1) IL235646A0 (enExample)
IN (1) IN2014DN10428A (enExample)
MX (1) MX2014015682A (enExample)
RU (1) RU2015101333A (enExample)
SG (1) SG11201407600UA (enExample)
WO (1) WO2013190292A2 (enExample)
ZA (1) ZA201408916B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533847A (ja) * 2012-10-24 2015-11-26 ポリセリックス・リミテッド 新規薬物−タンパク質コンジュゲート
JP2019532663A (ja) * 2016-11-07 2019-11-14 シアトル ジェネティックス， インコーポレイテッド 工学的に操作されたシステインキャップの分配
JP2021515793A (ja) * 2018-03-13 2021-06-24 ザイムワークス，インコーポレイテッド 抗ｈｅｒ２バイパラトピック抗体−薬物コンジュゲート及び使用方法
JP2022516032A (ja) * 2018-12-20 2022-02-24 スパイリーア リミテッド 抗体－薬物複合体

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2789793T3 (enExample) * 2012-10-24 2018-01-27
EP3964237B1 (en) 2013-03-15 2026-02-18 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
KR102252925B1 (ko) 2013-08-26 2021-05-18 리제너론 파마슈티칼스 인코포레이티드 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도
EP3145552B1 (en) 2014-05-23 2020-03-04 Novartis AG Methods for making conjugates from disulfide-containing proteins
WO2015187596A2 (en) * 2014-06-02 2015-12-10 Regeneron Pharmaceuticals, Inc. Biologically active molecule conjugates, reagents and methods of manufacture, and therapeutic uses
KR102463267B1 (ko) 2014-07-24 2022-11-03 제넨테크, 인크. 적어도 하나의 트리설파이드 결합을 함유하는 단백질에서 티올 모이어티에 제제의 접합 방법
WO2016059377A1 (en) 2014-10-14 2016-04-21 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
ES2960741T3 (es) * 2014-10-24 2024-03-06 Abzena Uk Ltd Conjugados y reactivos de conjugación
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
MA40725A (fr) * 2014-12-08 2017-10-18 Sorrento Therapeutics Inc Conjugué anticorps anti-c-met-médicament
KR20170102981A (ko) 2015-01-14 2017-09-12 브리스톨-마이어스 스큅 컴퍼니 헤테로아릴렌-가교된 벤조디아제핀 이량체, 그의 접합체, 및 제조 및 사용 방법
WO2016124781A1 (en) * 2015-02-05 2016-08-11 Ablynx N.V. Nanobody dimers linked via c-terminally engineered cysteins
KR20240142591A (ko) 2015-03-27 2024-09-30 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법
EP3331569A1 (en) 2015-08-07 2018-06-13 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
CN107029242A (zh) 2015-11-03 2017-08-11 财团法人工业技术研究院 抗体药物复合物及其制造方法
MY198605A (en) 2016-01-25 2023-09-08 Regeneron Pharma Maytansinoid derivatives conjugates thereof, and methods of use
WO2017178828A1 (en) * 2016-04-14 2017-10-19 Polytherics Limited Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring
GB201614162D0 (en) * 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
US11376317B2 (en) 2017-08-30 2022-07-05 University Of Maryland, College Park FcRn-targeted mucosal vaccination against RSV
US11591371B2 (en) 2018-04-02 2023-02-28 University Of Maryland, College Park FcRn-targeted mucosal vaccination against influenza infections
CN117679532A (zh) 2019-02-15 2024-03-12 上海药明合联生物技术有限公司 用于制备具有改善的同质性的抗体-药物缀合物的方法
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
CN115066263A (zh) * 2019-11-18 2022-09-16 克莱奥药品有限公司 定向缀合技术
WO2021174128A1 (en) * 2020-02-26 2021-09-02 University Of Maryland, College Park Compositions and methods for mucosal vaccination against sars-cov-2
WO2021115497A2 (zh) * 2020-12-08 2021-06-17 和铂医药(上海)有限责任公司 蛋白-药物偶联物和定点偶联方法
CN117147825A (zh) * 2022-05-29 2023-12-01 菲鹏生物股份有限公司 一种抗体缀合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521828A (ja) * 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
JP2015510877A (ja) * 2012-03-09 2015-04-13 ユーシーエル ビジネス パブリック リミテッド カンパニー 抗体の化学修飾

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
WO2009006520A1 (en) * 2007-07-03 2009-01-08 Medimmune, Llc Hinge domain engineering
PT2247620T (pt) * 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
WO2009130602A2 (en) * 2008-04-24 2009-10-29 Celtic Pharma Peg Ltd. Factor ix conjugates with extended half-lives
WO2011060018A2 (en) * 2009-11-13 2011-05-19 Ikaria Development Subsidiary Two Llc Compositions and methods for using peptides, modified peptides, peptidomimetics and fibrin derivatives
UY33827A (es) * 2010-12-22 2012-07-31 Abbott Lab Proteínas de unión a media-inmunoglobulina y sus usos

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008521828A (ja) * 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
JP2015510877A (ja) * 2012-03-09 2015-04-13 ユーシーエル ビジネス パブリック リミテッド カンパニー 抗体の化学修飾

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
ALLEN, M.J. ET AL., BIOCHEMISTRY, vol. 48, JPN6017012388, 2009, pages 3755 - 3766, ISSN: 0003534880 *
BROCCHINI, S. ET AL., ADV. DRUG DEL. REV., vol. 60, JPN6017012383, 2008, pages 3 - 12, ISSN: 0003534877 *
DEL ROSARIO, R.B. ET AL., BIOCONJUGATE CHEM., vol. 1, JPN6017012386, 1990, pages 51 - 59, ISSN: 0003534879 *
GLASER, S.M. ET AL., J. BIOL. CHEM., vol. 280, no. 50, JPN6017012393, 2005, pages 41494 - 41503, ISSN: 0003534883 *
GROULET, A. ET AL., INT. J. CANCER, vol. 100, JPN6017012390, 2002, pages 367 - 374, ISSN: 0003534870 *
KAN, K.S. ET AL., J. IMMUNOL., vol. 166, JPN6017012389, 2001, pages 1320 - 1326, ISSN: 0003534869 *
LIBERATORE, F.A. ET AL., BIOCONJUGATE CHEM., vol. 1, JPN6017012376, 1990, pages 36 - 50, ISSN: 0003534871 *
MCDONAGH, C.F. ET AL., PROTEIN ENG. DES. SEL., vol. 19, no. 7, JPN7017001224, 2006, pages 299 - 307, ISSN: 0003534875 *
RYAN, C.P. ET AL., CHEM. COMMUN., vol. 47, JPN6017012381, 2011, pages 5452 - 5454, ISSN: 0003534876 *
SCHUMACHER, F.F. ET AL., BIOCONJUGATE CHEM., vol. 22, JPN6017012385, 2011, pages 132 - 136, ISSN: 0003534878 *
SCHUURMAN, J. ET AL., MOL. IMMUNOL., vol. 38, JPN6017012392, 2001, pages 1 - 8, ISSN: 0003534882 *
SHAUNAK, S. ET AL., NAT. CHEM. BIOL., vol. 2, no. 6, JPN6017012378, 2006, pages 312 - 313, ISSN: 0003534873 *
SMITH, M.E.B. ET AL., J. AM. CHEM. SOC., vol. 132, JPN6017012391, 2010, pages 1960 - 1965, ISSN: 0003534881 *
WILBUR, D.S. ET AL., BIOCONJUGATE CHEM., vol. 5, JPN6017012377, 1994, pages 220 - 235, ISSN: 0003534872 *
免疫学辞典, vol. 第2版, JPN6017012379, 2001, pages 7 - 603, ISSN: 0003534874 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015533847A (ja) * 2012-10-24 2015-11-26 ポリセリックス・リミテッド 新規薬物−タンパク質コンジュゲート
JP2019532663A (ja) * 2016-11-07 2019-11-14 シアトル ジェネティックス， インコーポレイテッド 工学的に操作されたシステインキャップの分配
JP7073363B2 (ja) 2016-11-07 2022-05-23 シージェン インコーポレイテッド 工学的に操作されたシステインキャップの分配
JP2021515793A (ja) * 2018-03-13 2021-06-24 ザイムワークス，インコーポレイテッド 抗ｈｅｒ２バイパラトピック抗体−薬物コンジュゲート及び使用方法
JP7547205B2 (ja) 2018-03-13 2024-09-09 ザイムワークス ビーシー インコーポレイテッド 抗ｈｅｒ２バイパラトピック抗体－薬物コンジュゲート及び使用方法
US12357701B2 (en) 2018-03-13 2025-07-15 Zymeworks Bc Inc. Anti-HER2 biparatopic antibody-drug conjugates and methods of use
JP2022516032A (ja) * 2018-12-20 2022-02-24 スパイリーア リミテッド 抗体－薬物複合体

Also Published As

Publication number Publication date
CA2876365A1 (en) 2013-12-27
HK1204924A1 (en) 2015-12-11
IN2014DN10428A (enExample) 2015-08-21
WO2013190292A3 (en) 2014-03-20
EP2861261A2 (en) 2015-04-22
AU2013279099A1 (en) 2014-12-18
BR112014031613A2 (pt) 2017-07-25
ZA201408916B (en) 2015-11-25
US20150125473A1 (en) 2015-05-07
SG11201407600UA (en) 2014-12-30
KR20150023027A (ko) 2015-03-04
RU2015101333A (ru) 2016-08-10
CN104379178A (zh) 2015-02-25
WO2013190292A2 (en) 2013-12-27
MX2014015682A (es) 2015-07-23
IL235646A0 (en) 2015-01-29

Similar Documents

Publication Publication Date Title
US20150125473A1 (en) Novel process for preparation of antibody conjugates and novel antibody conjugates
JP6328648B2 (ja) 新規薬物−タンパク質コンジュゲート
TWI851552B (zh) 磷脂醯肌醇蛋白聚醣(glypican)3抗體及其結合物
JP2023052910A (ja) 可溶性タンパク質に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
ES2763579T3 (es) Estabilización de biomoléculas con polímeros de azúcar
JP2021523874A (ja) 抗メソセリン抗体およびその抗体薬物コンジュゲート
CN111094341A (zh) 在可变域和恒定域之间的肘区中具有功能域的抗体
AU2019233511B2 (en) Anti C-MET antibodies
CN118221804B (zh) 工程化抗体和包含工程化抗体的抗体-药物偶联物
CN117693526A (zh) 抗-c-Met抗体药物缀合物
WO2024227439A1 (zh) 具有靶向作用的偶联物及其制备方法和用途
JP2025020143A (ja) 切断可能なリンカーを含む化合物及びその使用
JP2023552733A (ja) 抗クローディン－１８．２抗体及びその抗体薬物複合体
CN116761824B (zh) 工程化抗-trop2抗体及其抗体-药物偶联物
TW201801746A (zh) Cd33抗體藥物結合物與化學治療劑之組合
WO2025214486A1 (zh) 抗Trop2抗体和抗5T4抗体-自然杀伤细胞偶联物及其用途
TWI908142B (zh) Nectin-4抗體及抗體藥物結合物
RU2814164C2 (ru) Антитело против клаудина 18.2 и его конъюгат антитело-лекарственное средство
RU2856361C2 (ru) Моноклональное антитело или его антигенсвязывающий фрагмент, которое специфически связывается с AXL, и его применение
EP4471061A1 (en) Anti-asct2-antibodies and adcs derived therefrom
JP2026514033A (ja) 抗ｃｄｈ６抗体－薬物コンジュゲート及びその使用
TW202542159A (zh) 新抗體藥物結合物以及其製造方法及用途
CN120393042A (zh) 含季铵盐的抗体偶联药物及其医药用途
WO2026046112A1 (zh) 一种靶向igf-1r的抗体及其应用
TW202606662A (zh) 蛋白質酪胺酸激酶7抗體及抗體藥物結合物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160602

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170410

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180205